If you are wondering whether Ionis Pharmaceuticals is still a smart buy after its big run, or if most of the upside is already reflected in the price, you are not alone. That is exactly what we are ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Fintel reports that on December 9, 2025, B of A Securities maintained coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Buy recommendation. Analyst Price Forecast Suggests 5.02% Upside As of ...

An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...

Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their ...

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and keeps a Buy rating on the shares ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially approved drugs for various diseases. Ionis has a ...

Ionis Pharmaceuticals (IONS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained the rating on the stock ...

Q1 revenue rises 10% to $132 million, exceeding the $125.3 million estimate; EPS loss improves to 93 cents vs. $1.12 consensus. 2025 revenue forecast raised to $725 million–$750 million from $600 ...

Ionis Pharmaceuticals, Inc. (IONS), the Carlsbad, California-based, commercial-stage pharmaceutical company, announced its Q4 and full-year 2023 earnings on Wednesday after the market close. Ionis ...

Royalty Pharma and Ionis Pharmaceuticals announced Monday morning a royalty agreement for up to $1.1 billion for Ionis’ royalty stakes in Biogen’s Spinraza and Novartis’ pelacarsen. As part of the ...